An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pear Therapeutics to Participate in 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced participation in the 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference from February 15-17. CEO Corey McCann will engage in a fireside chat on February 16 at 2:00 PM ET. The conference is exclusive to BTIG clients.
Pear Therapeutics is a leader in developing software-based medicines, known as prescription digital therapeutics (PDTs), with three products approved by the FDA targeting substance use disorder and chronic insomnia.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference, a virtual event taking place February 15 -17. Corey McCann, M.D., Ph.D., President and CEO, will participate in a fireside chat at 2:00 PM ET on Wednesday, February 16. Pear management will also participate in 1x1 meetings.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
What event will Pear Therapeutics participate in on February 16, 2022?
Pear Therapeutics will participate in the 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference on February 16, 2022.
Who will represent Pear Therapeutics at the BTIG Conference?
CEO Corey McCann will represent Pear Therapeutics at the BTIG Conference.
What is the stock symbol for Pear Therapeutics?
The stock symbol for Pear Therapeutics is PEAR.
What products does Pear Therapeutics specialize in?
Pear Therapeutics specializes in prescription digital therapeutics (PDTs) for treating substance use disorder and chronic insomnia.
What is the significance of the FDA approvals for Pear's products?
Pear Therapeutics' products are the first PDTs to receive FDA marketing authorization and breakthrough designation, indicating their innovative approach to treatment.
